Subscribe Sign In Register

Premium

OrbiMed gains on Amarin’s hearty rally

Amarin’s latest clinical test results suggest that the drug is on track to win Food and Drug Administration approval this year.

April 30, 2011
75pete-gallo.jpg

By Pete Gallo

null

null

Sam Isaly’s biotech and pharma hedge fund looks to have a winner on its hands.

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.

Amr101 Orbimed Amarin Sam Isaly
Related
icahn-0513-24v2b.png
Hedge Funds
Icahn’s Investment Fund Posts Small Loss
Stephen Taub
May 13, 2024
tigers-031924.jpeg
Hedge Funds
Tigers Sidestep Sell-Off
Stephen Taub
May 9, 2024
U.S. Election Voting Booths
Sponsored
The Relationship Between Elections and Volatility